Eli Lilly & Co (LLY)

Eli Lilly. Founded 1876, Indianapolis. Pharmaceutical conglomerate. Publicly traded on NASDAQ. Market cap by convention high (pharma tends toward scale). Revenue heavily concentrated in patent-protected drugs—oncology, insulin, immunology, rheumatology. Pipeline-dependent business model. Recurring theme: patent cliffs arrive on schedule, company must ship new approvals to offset revenue loss.

The business works backward from a simple fact: the company owns exclusive rights to dozens of drugs, rights granted by governments for a fixed term (in most countries, twenty years from patent filing). During that exclusive window, Eli Lilly sets the price. Competitors cannot enter. The company extracts very high margins—often 80 to 90 percent gross margin on branded drugs. When the patent expires, generic manufacturers can enter, prices collapse toward manufacturing cost, and Eli Lilly loses that revenue stream. Rinse, repeat. Pharmaceutical companies are therefore locked into a treadmill: research new drugs, win approvals, harvest profits during patent protection, and—crucially—develop the next generation of drugs before the old ones lose protection.

Eli Lilly’s origins trace to Eli Lilly himself, a pharmacist and entrepreneur. In 1876 he opened a small laboratory in Indianapolis and began manufacturing medicinal compounds from vegetable extracts. The company grew steadily, and by the mid-1900s it had become one of the leading drug manufacturers in America. Penicillin during World War II, then antibiotics, vitamins, and vaccines. But the modern Eli Lilly took shape beginning in the 1970s when the company made the strategic commitment to insulin—a hormone therapy essential for diabetes management. Eli Lilly did not invent insulin (it was discovered in the 1920s), but the company became the dominant producer. Insulin is a perpetual market—diabetics must take it every day for life—and Eli Lilly’s position became almost unshakeable.

The insulin franchise shaped the company’s entire identity. Insulin sales sustained profitability through the 1980s and 1990s while the company invested in research. It provided steady, predictable cash flow. Patients and physicians grew familiar with Eli Lilly’s insulin. Distribution networks locked into place. Over time Eli Lilly innovated on insulin too, moving from animal-derived insulin to human recombinant insulin to newer formulations designed to be faster-acting or longer-lasting, each iteration earning new patents and exclusivity periods. Patients switched to new formulations, Eli Lilly captured higher prices, and the cash flow funded expansion into other areas.

By the 2000s, Eli Lilly had diversified into oncology (cancer drugs), rheumatology (drugs for arthritis and autoimmune conditions), and immunology. These were growth areas where there was clinical need and where Eli Lilly could charge high prices. The company developed blockbuster drugs: Gemzar (pancreatic cancer), Tarceva (lung cancer), Humira (rheumatoid arthritis). Humira, in particular, became one of the most profitable drugs in the world—a biologic that modulates the immune system, prescribed to millions of patients with arthritis and other autoimmune conditions. It generated billions in annual revenue and was the company’s single largest profit center.

The structure of a modern pharmaceutical company: research chemists and biologists work in labs. They screen thousands of compounds looking for ones that interact with disease targets in useful ways. Promising compounds move into animal testing, then into human clinical trials—a process regulated by governments and designed to establish safety and efficacy. Successful trials lead to regulatory approval (in the United States, approval from the FDA). After approval, the company manufactures the drug, sells it through physicians and hospitals, and collects revenue during the exclusivity window. Manufacturing is straightforward chemistry; the real cost is in R&D and regulatory compliance.

Eli Lilly’s workforce is split between researchers (mostly concentrated in Indianapolis, but also in other sites), regulatory and clinical staff, and commercial teams (sales reps, medical liaisons) who promote the drugs to prescribers. The company operates manufacturing sites globally, both for active pharmaceutical ingredients and for finished dosages. Like all large pharma companies, Eli Lilly holds enormous patent portfolios and engages in complex licensing agreements with biotech companies and universities to access novel compounds.

Patent cliffs arrive predictably. Humira, which had sustained much of Eli Lilly’s profit in the late 2010s, faced its first biosimilar competition in 2023—biosimilars being generic-equivalent biologics that regulatory agencies allow to compete once patents expire. Revenue collapsed in months. The company’s answer had to be its pipeline: drugs in development that would replace Humira’s revenue. Two drugs Eli Lilly developed—tirzepatide (branded as Mounjaro) for diabetes and semaglutide-adjacent compounds for obesity—showed exceptional clinical efficacy and enormous market potential. Tirzepatide began driving revenue growth immediately after launch, offsetting Humira’s decline. The obesity space is particularly large: hundreds of millions of people worldwide are overweight or obese, and the prior standard treatment (lifestyle modification) had failed at scale. A drug that induced meaningful weight loss became a commercial sensation. Eli Lilly’s position in tirzepatide became strategically central—it was the company’s near-term growth engine.

The pharmaceutical industry operates on a handful of clear economic principles. Drugs that work attract high prices (the market will pay if the alternative is death or severe disease). Scale in manufacturing compounds economics. A drug that costs tens of millions of dollars to bring to market must generate billions in total revenue to justify the investment and generate shareholders’ return. Patent protection is everything—without exclusivity, competition destroys margins. Geographic variation matters: drugs in wealthy countries command higher prices than in poorer ones, leading to complex tiering and parallel-trade risk. And innovation is required to stay competitive—a company that relies on old drugs is in slow, inexorable decline.

Eli Lilly operates within that constraint. The company’s patent portfolio is valuable but finite. New approvals refresh it. Blockbuster drugs (those generating over a billion dollars annually) are the company’s lifeblood. The company monitors pipeline stage-by-stage—how many candidates are in early development, how many have entered human testing, how many are close to regulatory review—because those numbers forecast future revenue. A barren pipeline signals trouble ahead. Eli Lilly’s pipeline looked healthy in the mid-2020s, with multiple candidates in late-stage testing, but that success was concentrated in a few therapeutic areas (obesity, diabetes, oncology). Concentration is a risk—if a major candidate fails in trials, the impact is large.

Regulatory and political pressures mount. Governments around the world scrutinize high drug prices and have begun imposing price controls or negotiating discounts. In the United States, the Inflation Reduction Act granted Medicare the power to negotiate drug prices directly with manufacturers—a historic shift that threatens pharma margins. Other countries have long controlled prices. Eli Lilly’s pricing power, historically sacrosanct, is eroding. The company must ship genuinely innovative drugs that justify premium pricing, or face margin compression.

Research via SEC filings: the 10-K (CIK 0000059478) lays out segment revenue, R&D spending, pipeline stage, and patent expiration dates (critical for forecasting). Quarterly calls surface discussions of drug approvals, phase-trial results, and manufacturing or regulatory issues. Key metrics include R&D as a percentage of revenue (pharma invests heavily), gross margins by therapeutic area, and the number of drugs in each clinical phase. The pipeline table in the 10-K is essential—it forecasts future revenue and shows pipeline diversification. Patent expiration schedules tell you when cliffs are coming. Competitive environment matters too: which drugs are Eli Lilly’s main competitors, and what is the market share trend? For a pharma company, the fundamental question is always: can the pipeline replace declining revenue from patents that are expiring? Eli Lilly’s answer to that question determines its trajectory.